A Risk Stratification Model for Metastatic Lymph Nodes of Papillary Thyroid Cancer: A Retrospective Study Based on Sonographic Features

Ultrasound Diagnosis Two Cases of Multiple Primary Malignancies Neoplasms: Thyroid Carcinoma, Breast Carcinoma, and Non-Hodgkin Lymphoma

Multiple primary malignant neoplasms (MPMNs) refer to the simultaneous or sequential presence of two or more malignant tumors in a single individual, with the clear exclusion of the possibility of metastasis between these tumors. The combination of thyroid carcinoma, breast carcinoma, and non-Hodgkin lymphoma is a rare manifestation of MPMNs, and accurate identification and diagnosis of these cases hold significant clinical importance. Due to its high resolution, affordability, and capability for superficial examination, ultrasound is often the preferred method for evaluating the thyroid, breast, and lymph nodes. Currently, ultrasound can provide accurate assessments of the nature of nodules in these areas through two-dimensional imaging combined with fine-needle aspiration biopsy. This study will present the ultrasound findings and the results of ultrasound-guided needle aspiration biopsies from two cases of MPMNs involving thyroid cancer, breast cancer, and non-Hodgkin lymphoma.

Prognostic factors for postoperative papillary thyroid cancer with unexplained elevated Tg: A retrospective study

Objective

This study aimed to investigate the underlying reasons for unexplained elevated thyroglobulin (Tg) in postoperative papillary thyroid cancer (PTC) patients according to follow-up results post RAT and to explore the long-term clinical outcomes and prognostic factors associated with these patients.

Methods

From April 2016 to June 2019, a retrospective study was conducted on postoperative PTC patients who underwent RAT at our institution. Patients with preablative stimulated thyroglobulin (psTg) > 10 ng/mL but no structurally evident disease were enrolled. The causal categorization for elevated Tg was analyzed 6 months post RAT and the long-term therapeutic responses were assessed at the end of follow-up. To identify risk factors influencing recurrence-free survival (RFS), both univariate and multivariate Cox regression analysis were employed. Kaplan-Meier method was utilized for plotting survival curves.

Results

A cohort of 165 subjects was enrolled for the analyses. Based on the results of a six-month follow-up, the postoperative unexplained elevated Tg among 165 patients could be ultimately attributed to thyroid remnant in 13.94% (23/165), biochemical disease in 60.00% (99/165), and structural disease in 26.06% (43/165). With a median follow-up of 58 months, 51 (30.91%), 34 (20.60%), 21 (12.73%), and 59 (35.76%) of the 165 patients achieved ER, IDR, BIR and SIR, respectively. Univariate analysis showed that N stage, TNM stage and suppressed Tg 6 months post RAT may be prognostic factors affecting RFS. Multivariate analysis showed that N1b stage [HR:2.749, P = 0.003] and II/III stage [HR:2.910, P = 0.001] were independent risk factors for RFS.

Conclusion

The proportion of 165 postoperative PTC patients with unexplained elevated Tg developing structural disease within nearly 5 years was over 30%. Patients with N1b stage and higher TNM stage were more likely to develop structural disease.

Quantitative analysis of dual-phase enhanced CT in cervical lymph node metastasis of papillary thyroid carcinoma: a comparative study along with pathological manifestations

PURPOSE

This study aimed to investigate the diagnostic value of dual-phase enhanced computed tomography (CT) in the cervical lymph node metastasis (LNM) of papillary thyroid carcinoma (PTC) by analyzing the dual-phase enhanced Hounsfield units (HUs) of lymph node and sternocleidomastoid muscle, and the ratio and difference.

METHODS

The CT arterial-phase and venous-phase imaging data of 143 metastasis-positive lymph nodes (MPLNs) in 88 cases and 172 metastasis-negative lymph nodes (MNLNs) in 128 cases with PTC were retrospectively analyzed. All lymph nodes were confirmed by surgical pathology. The arterial-phase HU of lymph nodes (ANHU), venous-phase HU of lymph nodes (VNHU), arterial-phase HU of the sternocleidomastoid muscle (AMHU) and venous-phase HU of the sternocleidomastoid muscle (VMHU) were measured, and their difference and ratio (ANHU-AMHU, ANHU/AMHU, VNHU-VMHU, VNHU/VMHU) were calculated. The cutoff values and corresponding diagnostic efficacy for diagnosing LNM in PTC were sought by performing the receiver operating characteristic curves. The maximum pathological diameter (MPD) measured on pathological sections of lymph nodes was compared with the maximum transverse diameter (MTD) and maximum sagittal diameter (MSD) and their average values on CT images.

RESULTS

The ANHU, and VNHU of MPLNs and MNLNs were 111.89 ± 33.26 and 66.12 (56.81-76.86) (P < 0.001), and 99.07 ± 23.27 and 75.47 ± 13.95 (P < 0.001), respectively. The area under the curve, sensitivity, and specificity of the arterial-phase three parameters (ANHU, ANHU-AMHU, ANHU/AMHU) for diagnosing LNM were (0.877-0.880), (0.755-0.769), and (0.901-0.913), respectively, and the venous-phase three parameters (VNHU, VNHU-VMHU, VNHU/VMHU) were (0.801-0.817), (0.650-0.678), and (0.826-0.901), respectively. Compared with MPD, MTD (Z = -2.686, P = 0.007) and MSD (Z = -3.539, P < 0.001) were significantly different, while (MTD + MSD)/2 was not statistically different (Z = -0.038b, P = 0.969).

CONCLUSION

In the differential diagnosis of cervical LNM of PTC by dual-phase enhanced CT angiography, the arterial phase had higher diagnostic efficacy.

Diagnostic value of CT enhancement degree in lymph node metastasis of papillary thyroid cancer: A comparison of enhancement, ratio, and difference

OBJECTIVES

To evaluate the value of computed tomography (CT) enhancement degree in diagnosing lymph node (LN) metastasis in papillary thyroid carcinoma (PTC) by determining the ratio and difference between the Hounsfield units (HU) of CT enhancement and plain scan of the LNs, as well as between the HU of CT-enhanced LNs and the sternocleidomastoid muscle.

METHODS

The plain and enhanced CT findings of 114 metastasis-positive LNs in 89 cases and 143 metastasis-negative LNs in 114 cases of PTC were analyzed retrospectively. Plain HU of LNs (PN_HU), enhanced HU of LNs (EN_HU), and enhanced HU of the sternocleidomastoid muscle (EM_HU) were measured. The EN_HU, difference between EN_HU and PN_HU (EN-PN_HU), ratio of EN_HU to PN_HU (EN/PN_HU), difference between EN_HU and EM_HU (EN-EM_HU), and ratio of EN_HU to EM_HU (EN/EM_HU) in metastasis-positive and metastasis-negative LN groups were calculated, the corresponding diagnostic efficacy for differentiating metastasis-positive from metastasis-negative LNs in PTC were sought using the receiver-operating curve. The interobserver agreement between readers was assessed using the interobserver correlation coefficient (ICC).

RESULTS

The EN_HU of 114 metastasis-positive LNs and 143 metastasis-negative LNs was 113.39 ± 24.13 and 77.65 ± 15.93, EN-PN_HU was 65.84 ± 21.72 HU and 34.07 ± 13.63 HU, EN/PN_HU was 2.36 (1.98, 2.75) and 1.76 (1.54, 2.02), EN-EM_HU was 49.42 ± 24.59 HU and 13.27 ± 15.41 HU, and EN/EM_HU was 1.79 ± 0.40 and 1.21 ± 0.24, respectively (all P < 0.001). The area under the curve, cutoff value, sensitivity, specificity, and accuracy of EN_HU for identifying metastasis-positive and metastasis-negative LNs were 0.895, 97.3 HU, 0.746, 0.895, and 0.829, EN-PN_HU was 0.894, 47.8 HU, 0.807, 0.874, and 0.844, EN/PN_HU was 0.831, 1.9, 0.877, 0.650, and 0.751, EN-EM_HU was 0.890, 26.4 HU, 0.807, 0.839, and 0.825, and EN/EM_HU was 0.888, 1.5, 0.728, 0.902, and 0.825, respectively. The readers had an excellent interobserver agreement on these five parameters (ICC = 0.874-0.994).

CONCLUSION

In the preoperative evaluation of LN metastasis in PTC, EN_HU, EN-PN_HU, EN-EM_HU, and EN/EM_HU had similarly high diagnostic efficacy, with EN_HU, EN-PN_HU, and EN/EM_HU having higher specificity and EN-PN_HU and EN-EM_HU having higher sensitivity.